Yehuda Patt
#134,275
Most Influential Person Now
American cancer specialist
Yehuda Patt's AcademicInfluence.com Rankings
Yehuda Pattmedical Degrees
Medical
#2298
World Rank
#2713
Historical Rank
Oncology
#221
World Rank
#229
Historical Rank
Yehuda Pattphilosophy Degrees
Philosophy
#11643
World Rank
#16072
Historical Rank
Logic
#8450
World Rank
#10576
Historical Rank
Download Badge
Medical Philosophy
Yehuda Patt's Degrees
- Doctorate Medicine Harvard University
- PhD Biomedical Engineering Johns Hopkins University
Why Is Yehuda Patt Influential?
(Suggest an Edit or Addition)According to Wikipedia, Yehuda Patt is a liver cancer specialist, gastrointestinal oncologist, and Professor of Medicine at the University of New Mexico, and resides in Santa Fe, New Mexico. He was previously at the University of Texas, MD Anderson Cancer Center between the years 1975- 2003. He is the author of various papers pertaining to cancer and their effects on people, and has been cited numerous times for his writings and analyses.
Yehuda Patt's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus (2002) (738)
- Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. (1999) (284)
- Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case–Control Study (2007) (255)
- OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. (2005) (249)
- Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. (1994) (227)
- Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma (2004) (195)
- Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. (1988) (167)
- Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. (1998) (159)
- Phase II study of Taxol in patients with advanced gastric carcinoma. (1998) (159)
- Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. (2003) (156)
- Association between hypothyroidism and hepatocellular carcinoma: A case‐control study in the United States (2009) (144)
- Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. (1990) (138)
- The Role of Hepatitis C in Hepatocellular Carcinoma: A Case Control Study Among Egyptian Patients (2001) (137)
- Rising Prevalence of Hepatitis C Virus Infection Among Patients Recently Diagnosed With Hepatocellular Carcinoma in the United States (2002) (129)
- Colorectal carcinoma and brain metastasis: Distribution, treatment, and survival (1996) (124)
- Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. (1996) (123)
- Surgery After Downstaging of Unresectable Hepatic Tumors With Intra-Arterial Chemotherapy (2000) (114)
- Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy (1980) (109)
- Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. (1996) (106)
- Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver (1980) (98)
- Thalidomide in the treatment of patients with hepatocellular carcinoma (2005) (93)
- Hepatic artery infusion chemotherapy: gastroduodenal complications. (1981) (89)
- THE PALLIATIVE ROLE OF HEPATIC ARTERIAL INFUSION AND ARTERIAL OCCLUSION IN COLORECTAL CARCINOMA METASTATIC TO THE LIVER (1981) (87)
- Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. (1996) (83)
- Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. (1988) (82)
- Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case‐control study (2008) (80)
- The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. (2009) (79)
- Low serum alpha‐fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5‐fu and interferon‐alpha‐2b (1993) (73)
- Phase II Trial of Cisplatin, Interferon α-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer (2001) (72)
- Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction (2013) (71)
- Intraarterial cis‐platinum for patients with inoperable skeletal tumors (1981) (70)
- Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. (1994) (69)
- Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. (1989) (68)
- Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma (2017) (67)
- Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. (2000) (67)
- Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver (1987) (61)
- Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. (1997) (58)
- Nonsurgical treatment of hepatocellular carcinoma. (2001) (58)
- Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver (1983) (58)
- Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. (1990) (56)
- Feasibility of Adjuvant Hepatic Arterial Infusion of Chemotherapy After Radiofrequency Ablation With or Without Resection in Patients With Hepatic Metastases From Colorectal Cancer (2003) (52)
- Capecitabine Plus 3-Weekly Irinotecan (XELIRI Regimen) as First-Line Chemotherapy for Metastatic Colorectal Cancer: Phase II Trial Results (2007) (51)
- Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver (1988) (47)
- Infections associated with biliary drainage procedures in patients with cancer. (1991) (47)
- 99mTc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy. (1982) (45)
- Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. (1986) (44)
- Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. (1998) (42)
- Palliation of pelvic recurrence of colorectal cancer with intra‐arterial 5‐fluorouracil and mitomycin (1985) (42)
- Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. (1994) (42)
- Prognostic factors influencing survival of patients with advanced colorectal cancer: hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases. (1984) (40)
- Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. (2001) (38)
- Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. (1993) (37)
- Phase II trial of docetaxel for cholangiocarcinoma. (1999) (37)
- Arterial chemotherapy in the management of colorectal cancer: an overview. (1991) (35)
- The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. (1982) (35)
- Effective retreatment of patients with colorectal cancer and liver metastases. (1983) (34)
- Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. (1997) (32)
- Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. (1990) (32)
- Recombinant human interleukin‐11 improves thrombocytopenia in patients with cirrhosis (2003) (31)
- Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. (1994) (31)
- Modified cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma (2013) (30)
- Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. (1996) (30)
- Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. (1999) (29)
- Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. (1986) (29)
- Treatment of Hepatocellular Carcinoma in the Community: Disparities in Standard Therapy (2015) (29)
- Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. (1980) (28)
- Novel Systemic Therapy Options for Hepatocellular Carcinoma (2004) (26)
- Infectious complications of hepatic artery catheterization procedures in patients with cancer. (1991) (24)
- Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial (2004) (23)
- A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer (2010) (20)
- Regression of regionally confined melanoma with intra-arterial cis-dichlorodiammineplatinum(II). (1979) (20)
- Arterial complications from long-term hepatic artery chemoinfusion catheters: evaluation with CT. (1993) (20)
- Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb). (1988) (20)
- A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma (2008) (19)
- Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? (1999) (19)
- Phase II evaluation of recombinant alpha‐2a‐interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma (1993) (18)
- Enhancement of lung colony-forming efficiency by local thoracic irradiation: interpretation of labeled cell studies. (1978) (17)
- Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20 (2017) (17)
- A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). (2012) (16)
- Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. Experience with ZCE‐025 and IMMU‐4 monoclonal antibodies and proposed directions for clinical trials (1993) (16)
- Colorectal carcinoma metastases: detection with In-111-labeled monoclonal antibody CCR 086. (1990) (16)
- Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer Metastasis to the Liver (1998) (16)
- Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. (1987) (15)
- Nonsurgical treatment of hepatocellular carcinoma. (2001) (15)
- Immune restoration and/or augmentation of local xenogeneic graft versus host reaction by Cimetidine in vitro. (1981) (15)
- Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab' fragments. (1993) (15)
- Hepatic arterial infusion of Corynebacterium parvum and chemotherapy. (1978) (14)
- Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. (2004) (14)
- Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. (1997) (14)
- Prospective evaluation of thymosin fraction V immunotherapy in patients with non‐small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy (1984) (13)
- Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer (2017) (13)
- Local xenogeneic graft-vs-host reaction: a practical assessment of T cell function among cancer patients. (1979) (12)
- 99Tcm-IMMU4 imaging in recurrent colorectal cancer: Efficacy and impact on surgical management (1996) (12)
- Phase II study of didemnin B in advanced colorectal cancer (1992) (11)
- A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. (1990) (11)
- Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue. (1987) (10)
- Sequence of regional chemotherapy and surgery. Management of colorectal adenocarcinoma confined to the liver. (1981) (10)
- TREATMENT OF REGIONALLY CONFINED METASTATIC TUMORS WITH ARTERIAL INFUSION OF CISPLATIN (1980) (8)
- Does aflatoxin B 1 play a role in the etiology of hepatocellular carcinoma in the United States (1999) (8)
- 304 Capecitabine plus irinotecan (XELIRI) in first line metastatic colorectal cancer (MCRC): update on a phase II trial (2003) (8)
- Primary cardiac angiosarcoma. (1974) (8)
- A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers (2005) (7)
- Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC). (1986) (7)
- Regional Arterial Therapy in the Management of Primary Liver Neoplasms (1985) (6)
- Hepatic Arterial Infusion of Floxuridine, Adriamycin, and Mitomycin C for Primary Liver Neoplasms (1984) (6)
- NEW APPROACHES TO THE EVALUATION OF IMMUNOMODULATION BY THYMIC HORMONES * (1979) (5)
- A phase I‐II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver (1993) (5)
- Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma. (1985) (5)
- Liver cancer. (2001) (5)
- Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma (1990) (4)
- Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon. (1986) (4)
- A phase I study of intravenous azimexon therapy in human cancer. (1986) (4)
- Regional-Arterial Chemotherapy or Arterial Embolization in the Management of Various Stages of Colon Cancer (1985) (3)
- Percutaneous Transcatheter Arterial Embolization for Hypersplenism (1995) (3)
- Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer in the liver: why, how and what? (1988) (3)
- Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis. (2016) (3)
- Suppressor cell activity in cancer patients: a possible role for thymic hormones. (1978) (3)
- INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial (2017) (3)
- Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC). (2004) (3)
- Differential tumor regression in patients with bilobar hepatic metastases and dual arterial supply: evidence supporting the advantage of intra-arterial over intravenous route of drug delivery. (1989) (3)
- Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas (1991) (3)
- The immune restorative effect of cimetidine administration in vivo on local graft versus host (GVH) reaction of cancer patients (1982) (3)
- Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma (1991) (2)
- Superficial head and neck metastases in adults with widespread cancer. (1980) (2)
- A phase II trial of combination oxaliplatin, capecitabine, and celecoxib with concurrent radiation for patients with newly diagnosed resectable rectal cancer. (2013) (2)
- Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer. (2017) (2)
- Arteriovenous carcinoembryonic antigen gradient: determination by selective angiography for localization of metastatic colorectal cancer. (1980) (2)
- Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma (1993) (2)
- A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity (2008) (2)
- The therapy of osteosarcoma by intraarterial cis-platinum and limb preservation (1981) (2)
- Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC). (2010) (2)
- In-111 monoclonal antibody immunoscintigraphy of colorectal cancer. (1990) (2)
- The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma (1979) (1)
- Prognostic significance of initial immunological evaluation in stage 3B melanoma (M) treated with thymosin, BCG and DTIC (1977) (1)
- Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts). (2013) (1)
- Association between the job types and the risk of hepatocellular carcinoma in the United States (2016) (1)
- Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma : INST 0820 (2017) (1)
- In vitro immune augmentation by azimexon (AZ) and the cogener ciamexon (CI) is associated with increased IL-2 production (1985) (0)
- TRENDS IN HEPATOCELLULAR CARCINOMA IN NEW MEXICO, 1973-2002.: 232 (2007) (0)
- Ethnicity and hepatocellular carcinoma risk factors in New Mexico: A retrospective analysis over a 12-year period. (2017) (0)
- Phase II trial combining Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX-2 expression in relationship to outomces (2016) (0)
- Phase I I T rial o f S ystemic C ontinuous F luorouracil a nd Subcutaneous R ecombinant I nterferon A lfa-2b f or T reatment of H epatocellular C arcinoma (2003) (0)
- Phase II trial of sorafenib and capecitabine for hepatocellular carcinoma in cirrhotic patients. (2012) (0)
- CLINICAL EFFICACY OF 99mTc LABELED Fab1 FRAGMENT OF THE ANTICEA ANTIBODY IN PATIENTS WITH COLON CARCINOMA AND A RISING SERUM CEA (1992) (0)
- Immune restoration of cancer patients' graft versus host response (GVHR) by azimexon in vitro (1982) (0)
- Caring for the patient on intraarterial chemotherapy... are you ready? (1981) (0)
- Demographics from the ETHECC (Evaluation of THYMITAQ [nolatrexed dihydrochloride] in Hepatocellular Carcinoma [HCC]) trial population (2005) (0)
- Tc99m LABELED FAB?? MOAB ANTI-CEA (IMMU-4) FOR IMAGING OF OCCULT METASTATIC COLORECTAL CANCER IN PATIENTS WITH RISING SERUM CEA (1993) (0)
- In vitro and in vivo studies with azimexon in cancer patients (1982) (0)
- Arterial Therapy in the Management of Resectable and Nonresectable Metastatic Colorectal Cancer in the Liver (1988) (0)
- 18. CEA-SCAN™ can be used to predict resectability of recurrent colorectal cancer (1996) (0)
- MDAH Surgical Experience with Implantable Infusaid® Pumps and Medtronic Drug Administration Devices® (1988) (0)
- Phase II trial using combination of oxaliplatin, capecitabine, and celecoxib with concurrent radiation in patients with operable rectal cancer. (2010) (0)
- P-0028SORAFENIB AND CAPECITABINE FOR HEPATOCELLULAR CARCINOMA (HCC), A PHASE II TRIAL (2013) (0)
- Comparison between metastatic vs primary biliary tract cancer in their response to the Wallstent (1997) (0)
- CLINICAL UTILITY OF IMAGING WITH 99=TC-LABELED IMMU-4 Fab' FRAGMENT IN PATIENTS(pts) WITH CANCER OF THE COLON OR RECTUM (1994) (0)
- Title Page / Contents / Preface (1988) (0)
- P-325A Phase II trial using a combination of Oxaliplatin, Capecitabine, and Celecoxib with concurrent radiation for newly diagnosed resectable rectal cancer: COX2 expression in relationship to outcomes (2015) (0)
- Cisplatin, 5-Fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. (1995) (0)
- 232 TRENDS IN HEPATOCELLULAR CARCINOMA IN NEW MEXICO, 1973-2002. (2007) (0)
- Phase II Trial of Cisplatin , Interferon-2 b , Doxorubicin , and 5-Fluorouracil for Biliary Tract Cancer 1 (2001) (0)
- Endoscopic management of biliary tract cancer with the wallstent: Experience in 121 patients (1997) (0)
- Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum (1996) (0)
- A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. (1996) (0)
This paper list is powered by the following services:
Other Resources About Yehuda Patt
What Schools Are Affiliated With Yehuda Patt?
Yehuda Patt is affiliated with the following schools:
